Aperçu: G.M.
On
sait que le stress oxydatif élevé joue un rôle important dans le
développement de la dépression et du dysfonctionnement cognitif. À
ce jour, la thiorédoxine (TRX), une protéine antioxydante, a été
étudiée comme marqueur pour les troubles psychiatriques tels que la
schizophrénie, le trouble bipolaire et l'autisme, mais sa relation avec
la dépression est encore être inconnue.
Les résultats indiquent que les niveaux de TRX ne peuvent pas être utilisés comme marqueur pour le traitement des dépressions résistantes aux traitements.
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 22. pii: S0278-5846(16)30464-X. doi: 10.1016/j.pnpbp.2017.04.025.
Thioredoxin is not a marker for treatment-resistance depression but associated with cognitive function: An rTMS study
Aydın EP1, Genc A2, Dalkıran M2, Uyar ET2, Özer ÖA2, Karamustafalıoğlu KO2.
Author information
- 1
- Department of Psychiatry, Şişli Hamidiye Etfal Teaching and Research Hospital, Istanbul, Turkey. Electronic address: efruzpirdogan@gmail.com
- 2
- Department of Psychiatry, Şişli Hamidiye Etfal Teaching and Research Hospital, Istanbul, Turkey.
Abstract
Elevated
oxidative stress is known to play an important role in development of
depression and cognitive dysfunction. To date, thioredoxin (TRX), an
antioxidant protein, has been investigated as a marker for psychiatric
disorders such as schizophrenia, bipolar disorder and autism
but its relationship with depression is yet to be unknown. The aim of
this study is to detect the TRX levels in patients with
treatment-resistant depression (TRD), analyse the effect of rTMS
(repetitive transcranial magnetic stimulation) application on TRX levels
and display the relationship of TRX with cognitive areas. This study
included 27 treatment-resistant unipolar depression patients and 29
healthy subjects. Patients were evaluated by Hamilton Depression Scale
(HDRS), Hamilton Anxiety Scale (HARS) and Montreal Cognitive Assessment
(MoCA) before and after rTMS application. 23 of TRD patients were
applied high-frequency rTMS over left DLPFC for 2 to 4weeks and plasma
TRX levels of patients and healthy subjects were measured. No
significant difference was determined between the TRX levels of patients
and healthy subjects (p>0.05). After rTMS application there were
significant decrease in severity of depression (p<0.001) and anxiety
(p<0.001), and explicit improvement in cognitive areas (delayed
memory, visual-spatial/executive abilities and language points) (all
p<0.05). No difference was detected in TRX levels of the patients
after rTMS application (p>0.005). High language scores of the
patients were found to be associated with high TRX levels (p<0.005).
Our study indicates that TRX levels cannot be used as a marker for TRD
or rTMS treatment in TRD. In spite of this TRX levels have a positive
correlation with language functions of the patients of TRD. More
extensive studies are required to clarify the mechanism of action of TRX
and the effect of TRX on cognitive functions.
Copyright © 2017. Published by Elsevier Inc.
- PMID: 28442424
- DOI: 10.1016/j.pnpbp.2017.04.025
